Biogen Inc. (BIIB) and Eisai Co. Ltd. announced Friday morning that the Phase 2 study of BAN2401 in patients with early Alzheimer's disease demonstrated statistically significant slowing in progression of the disease and reduction of amyloid beta accumulated in the brain.
from RTT - Hot Stocks https://ift.tt/2m04gRC
via IFTTT
No comments:
Post a Comment